GlassScriptPhysician profile
James Herbert Gilbaugh
NPI 1952389728
$4,937.69
in general payments reported to CMS, 2019-2025
34 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,759 · 2020: $434 · 2021: $899 · 2022: $850 · 2023: $681 · 2024: $177 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $616.50 | 2019-2025 | Ams 700, Ams 700 Cxr Rte Kit |
| Medtronic, INC. | $457.13 | 2021-2022 | |
| Abbvie INC. | $387.18 | 2019-2023 | |
| Astellas Pharma US INC | $361.17 | 2019-2021 | |
| Janssen Biotech, INC. | $314.43 | 2019-2024 | Erleada |
| Medtronic USA, INC. | $310.86 | 2019 | |
| Sumitomo Pharma America, INC. | $217.14 | 2023-2024 | Gemtesa, Orgovyx |
| Axonics, INC. | $174.38 | 2021-2023 | Bulkamid, Axonics |
| Janssen Scientific Affairs, LLC | $168.49 | 2019 | |
| Endo Pharmaceuticals INC. | $164.04 | 2019-2021 | |
| Amgen INC. | $163.77 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $156.07 | 2023 | Adstiladrin |
| Pfizer INC. | $138.72 | 2019-2022 | |
| Allergan, INC. | $123.60 | 2019-2022 | |
| Progenics Pharmaceuticals, INC. | $122.63 | 2022-2024 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $121.72 | 2020-2023 | Provenge |
| Antares Pharma, INC. | $91.77 | 2020-2021 | |
| Procept Biorobotics Corporation | $91.26 | 2022 | |
| Neotract INC. | $89.33 | 2019-2020 | |
| Verity Pharmaceuticals INC. | $87.49 | 2021-2023 | Trelstar |
| Travere Therapeutics, INC. | $81.66 | 2019-2021 | |
| Coloplast Corp | $56.55 | 2021-2023 | Porges Coloplast |
| Tolmar Pharmaceuticals, INC. | $52.39 | 2020-2021 | |
| Conmed Corporation | $50.00 | 2019 | |
| Karl Storz Endoscopy-America | $48.69 | 2019 | |
| Olympus America INC. | $47.54 | 2021-2022 | |
| Photocure INC | $45.18 | 2019 | |
| Siemens Medical Solutions USA, INC. | $38.16 | 2021 | |
| Merck Sharp & Dohme LLC | $34.67 | 2021-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $31.19 | 2023 | |
| Urovant Sciences INC | $28.06 | 2021-2022 | |
| Coopersurgical, INC. | $25.31 | 2025 | Origio Sequential Fert |
| Davol INC. | $22.61 | 2019 | |
| Blue Earth Diagnostics | $18.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gilbaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.